Cesca Therapeutics to Present at Cell & Gene Therapy Bioprocessing & Commercialization 2017
September 25 2017 - 01:23PM
Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated
cell processing and point-of-care, autologous cell-based therapies,
today announced that Dalip Sethi, Ph.D., senior director of
research and development, will present at Cell & Gene Therapy
Bioprocessing & Commercialization 2017, which is being held
September 25-28 at the Hynes Convention Center in Boston. The
conference is part of Biotech Week Boston.
Dr. Sethi’s presentation, entitled “Designing
Clinical Trials for Success,” is scheduled for Wednesday, September
27 at 3:00pm ET. His presentation will address, among other topics,
the optimal design for late-stage clinical trials, as well as the
factors to be considered by drug developers when deciding between
conditional or full approval pathways.
For more information, please visit
https://lifesciences.knect365.com/cell-therapy-bioprocessing
About the Cell & Gene Therapy Bioprocessing and
Commercialization ConferenceCell & Gene Therapy
Bioprocessing & Commercialization 2017 is a gathering of
leading industry experts focused on relieving bottlenecks and pain
points in the clinical development, manufacture and
commercialization of cell, gene and immunotherapies.
About Cesca Therapeutics Inc.Cesca is a leading
regenerative medicine company that develops, commercializes and
markets a range of automated technologies for cell-based
therapeutics. Its device division, ThermoGenesis, provides a full
suite of solutions for automated clinical biobanking, point-of-care
applications, and automation for immuno-oncology. Cesca is also
leveraging its proprietary AutoXpress® technology platform to
develop autologous stem cell-based therapies that address
significant unmet needs in the vascular, cardiology and orthopedic
markets.
Forward-Looking StatementThe statements
contained herein may include statements of future expectations and
other forward-looking statements that are based on management’s
current views and assumptions and involve known and unknown risks
and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. A more complete description of risks that could cause
actual events to differ from the outcomes predicted by Cesca
Therapeutics' forward-looking statements is set forth under the
caption "Risk Factors" in Cesca Therapeutics’ annual report on Form
10-K and other reports it files with the Securities and Exchange
Commission from time to time, and you should consider each of those
factors when evaluating the forward-looking statements.
Company Contact: Cesca Therapeutics Inc.
ir@cescatherapeutics.com
Investor Contact: Rx CommunicationsPaula
Schwartz917-322-2216pschwartz@rxir.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Mar 2023 to Mar 2024